MedDataX Logo

New Anticoagulation Strategies of VV-ECMO

NCT ID: NCT03497338

Last Updated: 2021-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-01

Study Completion Date

2021-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effective and normative anticoagulation is one of the most important components of Extracorporeal membrane oxygenation (ECMO) management. Excessive anticoagulation may lead to hemorrhage, which is the most common and serious complication. Currently, the most common factors for monitoring anticoagulation of ECMO are the activated clotting time (ACT) and activated partial thromboplastin time (APTT). However, there is a lack of a unified understanding of the related monitoring measures, monitoring targets, and bleeding risk assessments, which have been chosen mainly because of experiences reported by various ECMO centers or the results of retrospective studies.Therefore, anticoagulation strategies need to be improved. Our research have found ECMO anticoagulation management should be transformed from monitoring only the APTT/activated clotting time (ACT) to considering the entire coagulation process. To maintain thrombosis ability and PLT function within normal ranges may help reduce hemorrhage rates and improve prognoses. This randomized controlled study aim to develop the safety and efficacy new anticoagulation strategies of VV-ECMO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD

NCT03261284

Extracorporeal Membrane Oxygenation Complication Thrombosis Hemorrhage +1 more
UNKNOWN NA

Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.

NCT02966080

Acute Respiratory Failure Extracorporeal Membrane Oxygenation Complication Bleeding
WITHDRAWN NA

Thrombin Generation as a New Test for Anticoagulation Management in Patients With ECMO

NCT03832842

Implantation of a Veno-arterial or Veno-venous ECMO
COMPLETED

Antithrombin Supplementation in ECMO

NCT03208270

Extracorporeal Membrane Oxygenation
COMPLETED PHASE2/PHASE3

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

NCT06676085

ECMO
RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age more than 18 years old, VV-ECMO is estimated more than 3 days

Exclusion Criteria

* hemorrhage before VV-ECMO established, VV-ECMO more than 48 hours before admitted, VV-ECMO is estimated less than 3 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xiao Tang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiao Tang

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of respiratory and critical care medicine,Beijing Chao-yang Hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

new anticoagulation of ECMO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation
NCT04133844 COMPLETED
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
NCT04925167 COMPLETED NA
Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure
NCT06038682 COMPLETED
Strategies for Anticoagulation During Venovenous ECMO
NCT04997265 COMPLETED NA
Bivalirudin vs Heparin in ECMO Patients
NCT03707418 WITHDRAWN PHASE1
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
NCT04412304 COMPLETED
Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism
NCT05382481 UNKNOWN NA
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching
NCT03483181 UNKNOWN
Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO
NCT05226442 COMPLETED PHASE2/PHASE3
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
NCT06275555 RECRUITING NA
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
NCT05006677 UNKNOWN
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
NCT02213978 COMPLETED
Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
NCT06442267 RECRUITING PHASE4
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
NCT06209892 NOT_YET_RECRUITING NA
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
NCT04496362 RECRUITING PHASE4
AntiCoagulation Tracking InterVention and Evaluation
NCT04059965 WITHDRAWN NA
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
NCT03666962 UNKNOWN
Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients
NCT04527042 UNKNOWN
Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients
NCT06010446 COMPLETED
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 COMPLETED PHASE3
Heparin-free Extracorporeal Membrane Oxygenation Support During Clinical Lung Transplantation
NCT05697692 UNKNOWN PHASE4
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
NCT01531829 UNKNOWN PHASE4
Gene-guided Warfarin for Anticoagulation Therapy
NCT04482842 WITHDRAWN NA
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
NCT03311984 UNKNOWN
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
NCT06662253 NOT_YET_RECRUITING PHASE2/PHASE3